BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 10660343)

  • 1. Characterization of an allelic variant in the nifedipine-specific element of CYP3A4: ethnic distribution and implications for prostate cancer risk. Mutations in brief no. 191. Online.
    Walker AH; Jaffe JM; Gunasegaram S; Cummings SA; Huang CS; Chern HD; Olopade OI; Weber BL; Rebbeck TR
    Hum Mutat; 1998; 12(4):289. PubMed ID: 10660343
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association between a CYP3A4 genetic variant and clinical presentation in African-American prostate cancer patients.
    Paris PL; Kupelian PA; Hall JM; Williams TL; Levin H; Klein EA; Casey G; Witte JS
    Cancer Epidemiol Biomarkers Prev; 1999 Oct; 8(10):901-5. PubMed ID: 10548319
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CYP3A4-V and prostate cancer in African Americans: causal or confounding association because of population stratification?
    Kittles RA; Chen W; Panguluri RK; Ahaghotu C; Jackson A; Adebamowo CA; Griffin R; Williams T; Ukoli F; Adams-Campbell L; Kwagyan J; Isaacs W; Freeman V; Dunston GM
    Hum Genet; 2002 Jun; 110(6):553-60. PubMed ID: 12107441
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ethnic differences in the frequency of prostate cancer susceptibility alleles at SRD5A2 and CYP3A4.
    Zeigler-Johnson CM; Walker AH; Mancke B; Spangler E; Jalloh M; McBride S; Deitz A; Malkowicz SB; Ofori-Adjei D; Gueye SM; Rebbeck TR
    Hum Hered; 2002; 54(1):13-21. PubMed ID: 12446983
    [TBL] [Abstract][Full Text] [Related]  

  • 5. More about: modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4.
    Rebbeck TR
    J Natl Cancer Inst; 2000 Jan; 92(1):76. PubMed ID: 10620637
    [No Abstract]   [Full Text] [Related]  

  • 6. CYP3A4 allelic variants with amino acid substitutions in exons 7 and 12: evidence for an allelic variant with altered catalytic activity.
    Sata F; Sapone A; Elizondo G; Stocker P; Miller VP; Zheng W; Raunio H; Crespi CL; Gonzalez FJ
    Clin Pharmacol Ther; 2000 Jan; 67(1):48-56. PubMed ID: 10668853
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Re: Modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4.
    Ando Y; Tateishi T; Sekido Y; Yamamoto T; Satoh T; Hasegawa Y; Kobayashi S; Katsumata Y; Shimokata K; Saito H
    J Natl Cancer Inst; 1999 Sep; 91(18):1587-90. PubMed ID: 10491442
    [No Abstract]   [Full Text] [Related]  

  • 8. Population distribution and effects on drug metabolism of a genetic variant in the 5' promoter region of CYP3A4.
    Ball SE; Scatina J; Kao J; Ferron GM; Fruncillo R; Mayer P; Weinryb I; Guida M; Hopkins PJ; Warner N; Hall J
    Clin Pharmacol Ther; 1999 Sep; 66(3):288-94. PubMed ID: 10511065
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4.
    Rebbeck TR; Jaffe JM; Walker AH; Wein AJ; Malkowicz SB
    J Natl Cancer Inst; 1998 Aug; 90(16):1225-9. PubMed ID: 9719084
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genetic signature consistent with selection against the CYP3A4*1B allele in non-African populations.
    Schirmer M; Toliat MR; Haberl M; Suk A; Kamdem LK; Klein K; Brockmöller J; Nürnberg P; Zanger UM; Wojnowski L
    Pharmacogenet Genomics; 2006 Jan; 16(1):59-71. PubMed ID: 16344723
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of a genetic variant in CYP3A4 on risk and clinical presentation of prostate cancer among white and African-American men.
    Bangsi D; Zhou J; Sun Y; Patel NP; Darga LL; Heilbrun LK; Powell IJ; Severson RK; Everson RB
    Urol Oncol; 2006; 24(1):21-7. PubMed ID: 16414488
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interindividual differences in hepatic expression of CYP3A4: relationship to genetic polymorphism in the 5'-upstream regulatory region.
    Westlind A; Löfberg L; Tindberg N; Andersson TB; Ingelman-Sundberg M
    Biochem Biophys Res Commun; 1999 May; 259(1):201-5. PubMed ID: 10334940
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genetic contribution to variable human CYP3A-mediated metabolism.
    Lamba JK; Lin YS; Schuetz EG; Thummel KE
    Adv Drug Deliv Rev; 2002 Nov; 54(10):1271-94. PubMed ID: 12406645
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Common allelic variants of cytochrome P4503A4 and their prevalence in different populations.
    Lamba JK; Lin YS; Thummel K; Daly A; Watkins PB; Strom S; Zhang J; Schuetz EG
    Pharmacogenetics; 2002 Mar; 12(2):121-32. PubMed ID: 11875366
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Human CYP1B1 Leu432Val gene polymorphism: ethnic distribution in African-Americans, Caucasians and Chinese; oestradiol hydroxylase activity; and distribution in prostate cancer cases and controls.
    Tang YM; Green BL; Chen GF; Thompson PA; Lang NP; Shinde A; Lin DX; Tan W; Lyn-Cook BD; Hammons GJ; Kadlubar FF
    Pharmacogenetics; 2000 Dec; 10(9):761-6. PubMed ID: 11221602
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CYP3A4 promoter variant in Saudi, Ghanaian and Scottish Caucasian populations.
    Tayeb MT; Clark C; Ameyaw MM; Haites NE; Evans DA; Tariq M; Mobarek A; Ofori-Adjei D; McLeod HL
    Pharmacogenetics; 2000 Nov; 10(8):753-6. PubMed ID: 11186137
    [No Abstract]   [Full Text] [Related]  

  • 17. CYP3A4 and CYP3A5 genotypes, haplotypes, and risk of prostate cancer.
    Plummer SJ; Conti DV; Paris PL; Curran AP; Casey G; Witte JS
    Cancer Epidemiol Biomarkers Prev; 2003 Sep; 12(9):928-32. PubMed ID: 14504207
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CYP3A4 promoter variant is associated with prostate cancer risk in men with benign prostate hyperplasia.
    Tayeb MT; Clark C; Sharp L; Haites NE; Rooney PH; Murray GI; Payne SN; McLeod HL
    Oncol Rep; 2002; 9(3):653-5. PubMed ID: 11956645
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CYP3A activity in African American and European American men: population differences and functional effect of the CYP3A4*1B5'-promoter region polymorphism.
    Wandel C; Witte JS; Hall JM; Stein CM; Wood AJ; Wilkinson GR
    Clin Pharmacol Ther; 2000 Jul; 68(1):82-91. PubMed ID: 10945319
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of variants of CYP3A4 and characterization of their abilities to metabolize testosterone and chlorpyrifos.
    Dai D; Tang J; Rose R; Hodgson E; Bienstock RJ; Mohrenweiser HW; Goldstein JA
    J Pharmacol Exp Ther; 2001 Dec; 299(3):825-31. PubMed ID: 11714865
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.